Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05472506
Title Oral AHR Antagonist in Combination With Nivolumab in Patients With Resistant or Recurrent Head and Neck Cancer
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Ikena Oncology

head and neck squamous cell carcinoma


KYN-175 + Nivolumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.